{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T23:36:32Z","timestamp":1785800192316,"version":"3.56.0"},"reference-count":72,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,2,1]],"date-time":"2020-02-01T00:00:00Z","timestamp":1580515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T00:00:00Z","timestamp":1582675200000},"content-version":"vor","delay-in-days":25,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000739","name":"University of Southampton","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100000739","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Osteoporos Rep"],"published-print":{"date-parts":[[2020,2]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Purpose of Review<\/jats:title>\n<jats:p>The assessment of fracture risk and use of antiosteoporosis medications have increased greatly over the last 20\u201330\u00a0years. However, despite this, osteoporosis care remains suboptimal worldwide. Even in patients who have sustained a fragility fracture, fewer than 20% actually receive appropriate antiosteoporosis therapy in the year following the fracture. There is also evidence that treatment rates have declined substantially in the last 5\u201310\u00a0years, in many countries. The goal of this article is to consider the causes for this decline and consider how this situation could be remedied.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Recent Findings<\/jats:title>\n<jats:p>A number of possible reasons, including the lack of prioritisation of osteoporosis therapy in ageing populations with multimorbidity, disproportionate concerns regarding the rare side effects of anti-resorptives and adverse changes in reimbursement in the USA, have been identified as contributing factors in poor osteoporosis care.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Summary<\/jats:title>\n<jats:p>Improved secondary prevention strategies; screening measures (primary prevention) and appropriate, cost-effective guideline and treatment threshold development could support the optimisation of osteoporosis care and prevention of future fractures.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s11914-020-00566-7","type":"journal-article","created":{"date-parts":[[2020,2,26]],"date-time":"2020-02-26T06:02:57Z","timestamp":1582696977000},"page":"38-46","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["General and Specific Considerations as to why Osteoporosis-Related Care Is Often Suboptimal"],"prefix":"10.1007","volume":"18","author":[{"given":"Elizabeth M","family":"Curtis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Woolford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Holmes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,2,26]]},"reference":[{"issue":"5","key":"566_CR1","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1007\/s00198-016-3894-y","volume":"28","author":"NC Harvey","year":"2017","unstructured":"Harvey NC, McCloskey EV, Mitchell PJ, Dawson-Hughes B, Pierroz DD, Reginster JY, et al. Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporos Int. 2017;28(5):1507\u201329.","journal-title":"Osteoporos Int"},{"issue":"5","key":"566_CR2","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.semarthrit.2005.11.001","volume":"35","author":"L Giangregorio","year":"2006","unstructured":"Giangregorio L, Papaioannou A, Cranney A, Zytaruk N, Adachi JD. Fragility fractures and the osteoporosis care gap: an international phenomenon. Semin Arthritis Rheum. 2006;35(5):293\u2013305.","journal-title":"Semin Arthritis Rheum"},{"issue":"9","key":"566_CR3","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1002\/jbmr.2301","volume":"29","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Svedbom A, Harvey N, McCloskey EV. The osteoporosis treatment gap. J Bone Miner Res. 2014;29(9):1926\u20138.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"566_CR4","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1007\/s11657-013-0166-8","volume":"9","author":"JA Kanis","year":"2014","unstructured":"Kanis JA, Johansson H, Oden A, Cooper C, McCloskey EV. Worldwide uptake of FRAX. Arch Osteoporos. 2014;9(1):166.","journal-title":"Arch Osteoporos"},{"issue":"9","key":"566_CR5","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1007\/s00198-012-1964-3","volume":"23","author":"JA Kanis","year":"2012","unstructured":"Kanis JA, Oden A, McCloskey EV, Johansson H, Wahl DA, Cooper C. A systematic review of hip fracture incidence and probability of fracture worldwide. Osteoporos Int. 2012;23(9):2239\u201356.","journal-title":"Osteoporos Int"},{"issue":"9","key":"566_CR6","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1002\/jbmr.2202","volume":"29","author":"DH Solomon","year":"2014","unstructured":"Solomon DH, Johnston SS, Boytsov NN, McMorrow D, Lane JM, Krohn KD. Osteoporosis medication use after hip fracture in U.S. patients between 2002 and 2011. J Bone Miner Res. 2014;29(9):1929\u201337.","journal-title":"J Bone Miner Res"},{"key":"566_CR7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","volume":"94","author":"RY van der Velde","year":"2016","unstructured":"van der Velde RY, Wyers CE, Teesselink E, Geusens PP, van den Bergh JP, de Vries F, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone. 2016;94:50\u20135.","journal-title":"Bone."},{"key":"566_CR8","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.bone.2014.06.011","volume":"66","author":"C Klop","year":"2014","unstructured":"Klop C, Welsing PM, Cooper C, Harvey NC, Elders PJ, Bijlsma JW, et al. Mortality in British hip fracture patients, 2000-2010: a population-based retrospective cohort study. Bone. 2014;66:171\u20137.","journal-title":"Bone."},{"issue":"11","key":"566_CR9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1002\/jbmr.2882","volume":"31","author":"Samuel Hawley","year":"2016","unstructured":"\u2022 Hawley S, Leal J, Delmestri A, Prieto-Alhambra D, Arden NK, Cooper C, et al. Anti-osteoporosis medication prescriptions and incidence of subsequent fracture among primary hip fracture patients in England and Wales: an interrupted time-series analysis. J Bone Miner Res. 2016;31(11):2008\u201315 A paper demonstrating the importance of national guidance and availability of cheaper generic antiosteoporosis medications on prescribing and subsequent fractures.","journal-title":"Journal of Bone and Mineral Research"},{"issue":"1","key":"566_CR10","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/s00198-016-3811-4","volume":"28","author":"A Shah","year":"2017","unstructured":"Shah A, Prieto-Alhambra D, Hawley S, Delmestri A, Lippett J, Cooper C, et al. Geographic variation in secondary fracture prevention after a hip fracture during 1999-2013: a UK study. Osteoporos Int. 2017;28(1):169\u201378.","journal-title":"Osteoporos Int"},{"issue":"3","key":"566_CR11","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1111\/j.1532-5415.2011.03854.x","volume":"60","author":"SL Greenspan","year":"2012","unstructured":"Greenspan SL, Wyman A, Hooven FH, Adami S, Gehlbach S, Anderson FA Jr, et al. Predictors of treatment with osteoporosis medications after recent fragility fractures in a multinational cohort of postmenopausal women. J Am Geriatr Soc. 2012;60(3):455\u201361.","journal-title":"J Am Geriatr Soc"},{"issue":"1\u20132","key":"566_CR12","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s11657-013-0137-0","volume":"8","author":"A Svedbom","year":"2013","unstructured":"Svedbom A, Hernlund E, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: a compendium of country-specific reports. Arch Osteoporos. 2013;8(1\u20132):137.","journal-title":"Arch Osteoporos"},{"key":"566_CR13","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.bone.2016.10.013","volume":"94","author":"RY van der Velde","year":"2017","unstructured":"van der Velde RY, Wyers CE, Teesselink E, Geusens PP, van den Bergh JP, de Vries F, et al. Trends in oral anti-osteoporosis drug prescription in the United Kingdom between 1990 and 2012: variation by age, sex, geographic location and ethnicity. Bone. 2017;94:50\u20135.","journal-title":"Bone."},{"issue":"1\u20132","key":"566_CR14","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1007\/s11657-013-0136-1","volume":"8","author":"E Hernlund","year":"2013","unstructured":"Hernlund E, Svedbom A, Ivergard M, Compston J, Cooper C, Stenmark J, et al. Osteoporosis in the European Union: medical management, epidemiology and economic burden : a report prepared in collaboration with the International Osteoporosis Foundation (IOF) and the European Federation of Pharmaceutical Industry Associations (EFPIA). Arch Osteoporos. 2013;8(1\u20132):136.","journal-title":"Arch Osteoporos"},{"issue":"1","key":"566_CR15","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s00198-012-2074-y","volume":"24","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster JY. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013;24(1):23\u201357.","journal-title":"Osteoporos Int"},{"issue":"9","key":"566_CR16","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1007\/s00198-012-1958-1","volume":"23","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257\u201376.","journal-title":"Osteoporos Int"},{"issue":"1","key":"566_CR17","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s11657-017-0324-5","volume":"12","author":"J Compston","year":"2017","unstructured":"Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N, et al. UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos. 2017;12(1):43.","journal-title":"Arch Osteoporos"},{"issue":"3","key":"566_CR18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.bone.2011.05.007","volume":"49","author":"A Diez-Perez","year":"2011","unstructured":"Diez-Perez A, Hooven FH, Adachi JD, Adami S, Anderson FA, Boonen S, et al. Regional differences in treatment for osteoporosis. The global longitudinal study of osteoporosis in women (GLOW). Bone. 2011;49(3):493\u20138.","journal-title":"Bone."},{"key":"566_CR19","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.bone.2017.08.031","volume":"105","author":"E Martin-Merino","year":"2017","unstructured":"Martin-Merino E, Huerta-Alvarez C, Prieto-Alhambra D, Alvarez-Gutierrez A, Montero-Corominas D. Secular trends of use of anti-osteoporotic treatments in Spain: a population-based cohort study including over 1.5million people and more than 12years of follow-up. Bone. 2017;105:292\u20138.","journal-title":"Bone"},{"key":"566_CR20","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.bone.2018.12.016","volume":"120","author":"B Abrahamsen","year":"2019","unstructured":"Abrahamsen B, Skjodt MK, Vestergaard P. Hip fracture rates and time trends in use of anti-osteoporosis medications in Denmark for the period 2005 to 2015: missed opportunities in fracture prevention. Bone. 2019;120:476\u201381.","journal-title":"Bone."},{"issue":"12","key":"566_CR21","doi-asserted-by":"crossref","first-page":"2179","DOI":"10.1002\/jbmr.2565","volume":"30","author":"S Jha","year":"2015","unstructured":"Jha S, Wang Z, Laucis N, Bhattacharyya T. Trends in media reports, oral bisphosphonate prescriptions, and hip fractures 1996-2012: an ecological analysis. J Bone Miner Res. 2015;30(12):2179\u201387.","journal-title":"J Bone Miner Res"},{"issue":"9","key":"566_CR22","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1007\/s00198-011-1713-z","volume":"22","author":"JA Kanis","year":"2011","unstructured":"Kanis JA, Hans D, Cooper C, Baim S, Bilezikian JP, Binkley N, et al. Interpretation and use of FRAX in clinical practice. Osteoporos Int. 2011;22(9):2395\u2013411.","journal-title":"Osteoporos Int."},{"issue":"1","key":"566_CR23","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-016-0278-z","volume":"11","author":"JA Kanis","year":"2016","unstructured":"Kanis JA, Harvey NC, Cooper C, Johansson H, Oden A, McCloskey EV. A systematic review of intervention thresholds based on FRAX: a report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016;11(1):25.","journal-title":"Arch Osteoporos"},{"issue":"9","key":"566_CR24","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1007\/s00198-015-3154-6","volume":"26","author":"A Oden","year":"2015","unstructured":"Oden A, McCloskey EV, Kanis JA, Harvey NC, Johansson H. Burden of high fracture probability worldwide: secular increases 2010-2040. Osteoporos Int. 2015;26(9):2243\u20138.","journal-title":"Osteoporos Int"},{"key":"566_CR25","unstructured":"Global Burden of Disease Study 2013 Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 301 acute and chronic diseases and injuries in 188 countries, 1990\u20132013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;386(9995):743\u2013800."},{"issue":"2","key":"566_CR26","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrrheum.2009.260","volume":"6","author":"N Harvey","year":"2010","unstructured":"Harvey N, Dennison E, Cooper C. Osteoporosis: impact on health and economics. Nat Rev Rheumatol. 2010;6(2):99\u2013105.","journal-title":"Nat Rev Rheumatol."},{"issue":"9","key":"566_CR27","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1503\/cmaj.080295","volume":"179","author":"PC Austin","year":"2008","unstructured":"Austin PC, Tu JV, Ko DT, Alter DA. Factors associated with the use of evidence-based therapies after discharge among elderly patients with myocardial infarction. CMAJ. 2008;179(9):901\u20138.","journal-title":"CMAJ."},{"issue":"1","key":"566_CR28","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1007\/s00198-010-1211-8","volume":"22","author":"ES Siris","year":"2011","unstructured":"Siris ES, Gehlbach S, Adachi JD, Boonen S, Chapurlat RD, Compston JE, et al. Failure to perceive increased risk of fracture in women 55 years and older: the global longitudinal study of osteoporosis in women (GLOW). Osteoporos Int. 2011;22(1):27\u201335.","journal-title":"Osteoporos Int"},{"key":"566_CR29","doi-asserted-by":"crossref","first-page":"h2088","DOI":"10.1136\/bmj.h2088","volume":"350","author":"TL J\u00e4rvinen","year":"2015","unstructured":"J\u00e4rvinen TL, Micha\u00eblsson K, Jokihaara J, Collins GS, Perry TL, Mintzes B, et al. Overdiagnosis of bone fragility in the quest to prevent hip fracture. BMJ. 2015;350:h2088.","journal-title":"BMJ"},{"issue":"6","key":"566_CR30","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1111\/joim.12366","volume":"277","author":"TLN J\u00e4rvinen","year":"2015","unstructured":"J\u00e4rvinen TLN, Micha\u00eblsson K, Aspenberg P, Siev\u00e4nen H. Osteoporosis: the emperor has no clothes. J Intern Med. 2015;277(6):662\u201373.","journal-title":"J Intern Med"},{"issue":"8","key":"566_CR31","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s00198-015-3220-0","volume":"26","author":"J Compston","year":"2015","unstructured":"Compston J. Overdiagnosis of osteoporosis: fact or fallacy? Osteoporos Int. 2015;26(8):2051\u20134.","journal-title":"Osteoporos Int"},{"issue":"12","key":"566_CR32","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1007\/s40618-018-0898-9","volume":"41","author":"C Cipriani","year":"2018","unstructured":"Cipriani C, Pepe J, Minisola S, Lewiecki EM. Adverse effects of media reports on the treatment of osteoporosis. J Endocrinol Investig. 2018;41(12):1359\u201364.","journal-title":"J Endocrinol Investig"},{"issue":"12","key":"566_CR33","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1002\/pds.3703","volume":"23","author":"G Peeters","year":"2014","unstructured":"Peeters G, Tett SE, Duncan EL, Mishra GD, Dobson AJ. Osteoporosis medication dispensing for older Australian women from 2002 to 2010: influences of publications, guidelines, marketing activities and policy. Pharmacoepidemiol Drug Saf. 2014;23(12):1303\u201311.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"566_CR34","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/jbmr.2708","volume":"31","author":"RA Adler","year":"2016","unstructured":"Adler RA, El-Hajj Fuleihan G, Bauer DC, Camacho PM, Clarke BL, Clines GA, et al. Managing osteoporosis in patients on long-term bisphosphonate treatment: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16\u201335.","journal-title":"J Bone Miner Res"},{"key":"566_CR35","doi-asserted-by":"crossref","first-page":"i4843","DOI":"10.1136\/bmj.i4843","volume":"354","author":"C Farmer","year":"2016","unstructured":"Farmer C, Fenu E, O'Flynn N, Guthrie B. Clinical assessment and management of multimorbidity: summary of NICE guidance. BMJ. 2016;354:i4843.","journal-title":"BMJ."},{"issue":"3","key":"566_CR36","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMcp1513724","volume":"374","author":"DM Black","year":"2016","unstructured":"Black DM, Rosen CJ. Clinical Practice. Postmenopausal Osteoporosis. N Engl J Med. 2016;374(3):254\u201362.","journal-title":"N Engl J Med"},{"issue":"8","key":"566_CR37","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1002\/jbmr.1893","volume":"28","author":"L Gedmintas","year":"2013","unstructured":"Gedmintas L, Solomon DH, Kim SC. Bisphosphonates and risk of subtrochanteric, femoral shaft, and atypical femur fracture: a systematic review and meta-analysis. J Bone Miner Res. 2013;28(8):1729\u201337.","journal-title":"J Bone Miner Res"},{"issue":"2","key":"566_CR38","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1210\/er.2018-00001","volume":"40","author":"Dennis M Black","year":"2018","unstructured":"\u2022 Black DM, Abrahamsen B, Bouxsein ML, Einhorn T, Napoli N. Atypical femur fractures: review of epidemiology, relationship to bisphosphonates, prevention, and clinical management. Endocr Rev. 2019;40(2):333\u201368 A key, up to date review on atypical femoral fractures, how to prevent and manage them.","journal-title":"Endocrine Reviews"},{"issue":"4","key":"566_CR39","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/jbmr.1808","volume":"28","author":"JP Brown","year":"2013","unstructured":"Brown JP, Roux C, T\u00f6rring O, Ho P-R, Beck Jensen J-E, Gilchrist N, et al. Discontinuation of denosumab and associated fracture incidence: analysis from the fracture reduction evaluation of denosumab in osteoporosis every 6 months (FREEDOM) trial. J Bone Miner Res. 2013;28(4):746\u201352.","journal-title":"J Bone Miner Res"},{"key":"566_CR40","doi-asserted-by":"crossref","first-page":"i3365","DOI":"10.1136\/bmj.i3365","volume":"353","author":"B Abrahamsen","year":"2016","unstructured":"Abrahamsen B, Eiken P, Prieto-Alhambra D, Eastell R. Risk of hip, subtrochanteric, and femoral shaft fractures among mid and long term users of alendronate: nationwide cohort and nested case-control study. Bmj. 2016;353:i3365.","journal-title":"Bmj."},{"issue":"9","key":"566_CR41","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1007\/s00198-019-05002-w","volume":"30","author":"E.M. Dennison","year":"2019","unstructured":"\u2022\u2022 Dennison EM, Cooper C, Kanis JA, Bruyere O, Silverman S, McCloskey E, et al. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019;30(9):1733\u201343. A new systematic review on intermission of osteoporosis therapy, known as \u201ctreatment holidays\u201d, led by the International Osteoporosis Foundation.","journal-title":"Osteoporosis International"},{"key":"566_CR42","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1007\/s11657-013-0144-1","volume":"8","author":"JA Kanis","year":"2013","unstructured":"Kanis JA, Borgstrom F, Compston J, Dreinhofer K, Nolte E, Jonsson L, et al. SCOPE: a scorecard for osteoporosis in Europe. Arch Osteoporos. 2013;8:144.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"566_CR43","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.jocd.2015.01.005","volume":"18","author":"RA Overman","year":"2015","unstructured":"Overman RA, Farley JF, Curtis JR, Zhang J, Gourlay ML, Deal CL. DXA utilization between 2006 and 2012 in commercially insured younger postmenopausal women. J Clin Densitom. 2015;18(2):145\u20139.","journal-title":"J Clin Densitom"},{"key":"566_CR44","unstructured":"Lewiecki EM, Adler RA, Curtis J, Gagel RF, Saag KG, Singer A, et al. Hip fractures and declining DXA testing: at a breaking point? J Bone Miner Res. 2016. American Society for Bone and Mineral Research Annual Scientific Meeting (Abstract 1077)."},{"issue":"1","key":"566_CR45","doi-asserted-by":"crossref","first-page":"e69","DOI":"10.1016\/j.whi.2013.11.007","volume":"24","author":"ML Grover","year":"2014","unstructured":"Grover ML, Edwards FD, Chang YH, Cook CB, Behrens MC, Dueck AC. Fracture risk perception study: patient self-perceptions of bone health often disagree with calculated fracture risk. Womens Health Issues. 2014;24(1):e69\u201375.","journal-title":"Womens Health Issues"},{"issue":"1","key":"566_CR46","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1007\/s00198-013-2438-y","volume":"25","author":"CL Gregson","year":"2014","unstructured":"Gregson CL, Dennison EM, Compston JE, Adami S, Adachi JD, Anderson FA Jr, et al. Disease-specific perception of fracture risk and incident fracture rates: GLOW cohort study. Osteoporos Int. 2014;25(1):85\u201395.","journal-title":"Osteoporos Int"},{"issue":"10","key":"566_CR47","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1002\/jbmr.1698","volume":"27","author":"JA Eisman","year":"2012","unstructured":"Eisman JA, Bogoch ER, Dell R, Harrington JT, McKinney RE Jr, McLellan A, et al. Making the first fracture the last fracture: ASBMR task force report on secondary fracture prevention. J Bone Miner Res. 2012;27(10):2039\u201346.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"566_CR48","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s11914-012-0130-3","volume":"11","author":"PJ Mitchell","year":"2013","unstructured":"Mitchell PJ. Best practices in secondary fracture prevention: fracture liaison services. Curr Osteoporos Rep. 2013;11(1):52\u201360.","journal-title":"Curr Osteoporos Rep"},{"issue":"5","key":"566_CR49","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1007\/s00198-015-3452-z","volume":"27","author":"S. Drew","year":"2016","unstructured":"\u2022 Drew S, Judge A, Cooper C, Javaid MK, Farmer A, Gooberman-Hill R. Secondary prevention of fractures after hip fracture: a qualitative study of effective service delivery. Osteoporos Int. 2016;27(5):1719\u201327 A paper discussing ways of developing best models of secondary fracture prevention after hip fracture, through structured interviewing of health professionals.","journal-title":"Osteoporosis International"},{"issue":"8","key":"566_CR50","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1007\/s00198-013-2348-z","volume":"24","author":"K Akesson","year":"2013","unstructured":"Akesson K, Marsh D, Mitchell PJ, McLellan AR, Stenmark J, Pierroz DD, et al. Capture the fracture: a best practice framework and global campaign to break the fragility fracture cycle. Osteoporos Int. 2013;24(8):2135\u201352.","journal-title":"Osteoporos Int"},{"issue":"11","key":"566_CR51","doi-asserted-by":"crossref","first-page":"2573","DOI":"10.1007\/s00198-015-3192-0","volume":"26","author":"MK Javaid","year":"2015","unstructured":"Javaid MK, Kyer C, Mitchell PJ, Chana J, Moss C, Edwards MH, et al. Effective secondary fracture prevention: implementation of a global benchmarking of clinical quality using the IOF capture the fracture(R) best practice framework tool. Osteoporos Int. 2015;26(11):2573\u20138.","journal-title":"Osteoporos Int"},{"issue":"3","key":"566_CR52","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/j.berh.2016.09.008","volume":"30","author":"P Mitchell","year":"2016","unstructured":"Mitchell P, Akesson K, Chandran M, Cooper C, Ganda K, Schneider M. Implementation of models of care for secondary osteoporotic fracture prevention and orthogeriatric models of care for osteoporotic hip fracture. Best Pract Res Clin Rheumatol. 2016;30(3):536\u201358.","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"2","key":"566_CR53","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1002\/jbmr.5650070214","volume":"7","author":"C Cooper","year":"1992","unstructured":"Cooper C, Atkinson EJ, O'Fallon WM, Melton LJ. Incidence of clinically diagnosed vertebral fractures: a population-based study in Rochester, Minnesota, 1985-1989. J Bone Miner Res. 1992;7(2):221\u20137.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"566_CR54","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1002\/jbmr.1478","volume":"27","author":"EM Clark","year":"2012","unstructured":"Clark EM, Gould V, Morrison L, Ades AE, Dieppe P, Tobias JH. Randomized controlled trial of a primary care-based screening program to identify older women with prevalent osteoporotic vertebral fractures: cohort for skeletal health in Bristol and Avon (COSHIBA). J Bone Miner Res. 2012;27(3):664\u201371.","journal-title":"J Bone Miner Res"},{"issue":"4","key":"566_CR55","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1007\/s00198-015-3397-2","volume":"27","author":"EM Clark","year":"2016","unstructured":"Clark EM, Gooberman-Hill R, Peters TJ. Using self-reports of pain and other variables to distinguish between older women with back pain due to vertebral fractures and those with back pain due to degenerative changes. Osteoporos Int. 2016;27(4):1459\u201367.","journal-title":"Osteoporos Int"},{"issue":"4","key":"566_CR56","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/jbmr.3220","volume":"33","author":"L Oei","year":"2018","unstructured":"Oei L, Koromani F, Breda SJ, Schousboe JT, Clark EM, van Meurs JB, et al. Osteoporotic vertebral fracture prevalence varies widely between qualitative and quantitative radiological assessment methods: the Rotterdam study. J Bone Miner Res. 2018;33(4):560\u20138.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"566_CR57","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1007\/s00330-018-5846-8","volume":"29","author":"UJ Muehlematter","year":"2019","unstructured":"Muehlematter UJ, Mannil M, Becker AS, Vokinger KN, Finkenstaedt T, Osterhoff G, et al. Vertebral body insufficiency fractures: detection of vertebrae at risk on standard CT images using texture analysis and machine learning. Eur Radiol. 2019;29(5):2207\u201317.","journal-title":"Eur Radiol"},{"issue":"10","key":"566_CR58","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1007\/s00198-014-2794-2","volume":"25","author":"F Cosman","year":"2014","unstructured":"Cosman F, de Beur SJ, LeBoff MS, Lewiecki EM, Tanner B, Randall S, et al. Clinician\u2019s guide to prevention and treatment of osteoporosis. Osteoporos Int. 2014;25(10):2359\u201381.","journal-title":"Osteoporos Int"},{"issue":"1\u20132","key":"566_CR59","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s11657-012-0070-7","volume":"7","author":"S Lekamwasam","year":"2012","unstructured":"Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. An appendix to the 2012 IOF-ECTS guidelines for the management of glucocorticoid-induced osteoporosis. Arch Osteoporos. 2012;7(1\u20132):25\u201330.","journal-title":"Arch Osteoporos"},{"issue":"10","key":"566_CR60","doi-asserted-by":"crossref","first-page":"2507","DOI":"10.1007\/s00198-011-1876-7","volume":"23","author":"L Shepstone","year":"2012","unstructured":"Shepstone L, Fordham R, Lenaghan E, Harvey I, Cooper C, Gittoes N, et al. A pragmatic randomised controlled trial of the effectiveness and cost-effectiveness of screening older women for the prevention of fractures: rationale, design and methods for the SCOOP study. Osteoporos Int. 2012;23(10):2507\u201315.","journal-title":"Osteoporos Int"},{"issue":"10122","key":"566_CR61","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","volume":"391","author":"Lee Shepstone","year":"2018","unstructured":"\u2022\u2022 Shepstone L, Lenaghan E, Cooper C, Clarke S, Fong-Soe-Khioe R, Fordham R, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741\u20137 A randomised controlled trial of community screening for fracture risk in UK women demonstrating a reduction in hip fractures in screened women.","journal-title":"The Lancet"},{"issue":"6","key":"566_CR62","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1002\/jbmr.3411","volume":"33","author":"E McCloskey","year":"2018","unstructured":"McCloskey E, Johansson H, Harvey NC, Shepstone L, Lenaghan E, Fordham R, et al. Management of patients with high baseline hip fracture risk by FRAX reduces hip fractures-a post hoc analysis of the SCOOP study. J Bone Miner Res. 2018;33(6):1020\u20136.","journal-title":"J Bone Miner Res"},{"issue":"5","key":"566_CR63","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/jbmr.3381","volume":"33","author":"DA Turner","year":"2018","unstructured":"Turner DA, Khioe RFS, Shepstone L, Lenaghan E, Cooper C, Gittoes N, et al. The cost-effectiveness of screening in the community to reduce osteoporotic fractures in older women in the UK: economic evaluation of the SCOOP study. J Bone Miner Res. 2018;33(5):845\u201351.","journal-title":"J Bone Miner Res"},{"issue":"3","key":"566_CR64","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s00198-017-4326-3","volume":"29","author":"KH Rubin","year":"2018","unstructured":"Rubin KH, Rothmann MJ, Holmberg T, Hoiberg M, Moller S, Barkmann R, et al. Effectiveness of a two-step population-based osteoporosis screening program using FRAX: the randomized risk-stratified osteoporosis strategy evaluation (ROSE) study. Osteoporos Int. 2018;29(3):567\u201378.","journal-title":"Osteoporos Int"},{"issue":"24","key":"566_CR65","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1001\/jama.2018.6537","volume":"319","author":"M Viswanathan","year":"2018","unstructured":"Viswanathan M, Reddy S, Berkman N, Cullen K, Middleton JC, Nicholson WK, et al. Screening to prevent osteoporotic fractures: updated evidence report and systematic review for the US preventive services task force USPSTF evidence report: screening to prevent osteoporotic FracturesUSPSTF evidence report: screening to prevent osteoporotic fractures. JAMA. 2018;319(24):2532\u201351.","journal-title":"JAMA."},{"key":"566_CR66","volume-title":"TA464: bisphosphonates for treating osteoporosis","author":"NICE","year":"2017","unstructured":"NICE. TA464: bisphosphonates for treating osteoporosis. London: National Institute for Health and Care Excellence; 2017."},{"issue":"10109","key":"566_CR67","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(17)32850-7","volume":"390","author":"Nicholas C Harvey","year":"2017","unstructured":"Harvey NC, McCloskey E, Kanis J, Compston J, Cooper C. Bisphosphonates in osteoporosis: NICE and easy? Lancet. 2017;390(10109):2243\u20134.","journal-title":"The Lancet"},{"issue":"7","key":"566_CR68","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1007\/s00198-018-4505-x","volume":"29","author":"NC Harvey","year":"2018","unstructured":"Harvey NC, McCloskey E, Kanis JA, Compston J, Cooper C. Cost-effective but clinically inappropriate: new NICE intervention thresholds in osteoporosis (technology appraisal 464). Osteoporos Int. 2018;29(7):1511\u20133.","journal-title":"Osteoporos Int"},{"issue":"11","key":"566_CR69","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S2213-8587(17)30188-2","volume":"5","author":"Sundeep Khosla","year":"2017","unstructured":"\u2022\u2022 Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2017;5(11):898\u2013907 An important review article addressing the problem of osteoporosis treatment acceptance amongst patients and strategies to address this.","journal-title":"The Lancet Diabetes & Endocrinology"},{"key":"566_CR70","unstructured":"\u2022\u2022 Harvey NC, McCloskey E. Gaps and solutions in bone health: a global framework for improvement. 2016. https:\/\/www.iofbonehealth.org\/thematicreport-2016. A report produced by the International Osteoporosis Foundation to describe 10 key care gaps which are hindering osteoporosis treatment and fracture prevention worldwide."},{"key":"566_CR71","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/B978-0-12-801238-3.99202-X","volume-title":"Encyclopedia of endocrine diseases","author":"NCW Harvey","year":"2019","unstructured":"Harvey NCW, McCloskey EV, Rizzoli R, Kanis JA, Cooper C, Reginster J-Y. Osteoporosis: treatment gaps and health economics. In: Huhtaniemi I, Martini L, editors. Encyclopedia of endocrine diseases. Second ed. Oxford: Academic Press; 2019. p. 288\u201395.","edition":"Second"},{"issue":"10","key":"566_CR72","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1007\/s40618-019-01041-6","volume":"42","author":"J Liu","year":"2019","unstructured":"Liu J, Curtis EM, Cooper C, Harvey NC. State of the art in osteoporosis risk assessment and treatment. J Endocrinol Investig. 2019;42(10):1149\u201364.","journal-title":"J Endocrinol Investig"}],"container-title":["Current Osteoporosis Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00566-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11914-020-00566-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11914-020-00566-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,25]],"date-time":"2021-02-25T00:49:15Z","timestamp":1614214155000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11914-020-00566-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,2]]},"references-count":72,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,2]]}},"alternative-id":["566"],"URL":"https:\/\/doi.org\/10.1007\/s11914-020-00566-7","relation":{},"ISSN":["1544-1873","1544-2241"],"issn-type":[{"value":"1544-1873","type":"print"},{"value":"1544-2241","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,2]]},"assertion":[{"value":"26 February 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"EC reports honoraria\/travel support from Eli Lilly, UCB and Amgen outside the submitted work. JL has no disclosures. CH reports no disclosures. CC reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. NCH reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, Consilient Healthcare and Internis Pharma, outside the submitted work.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}},{"value":"This review article does not present any previously unpublished original research, and ethical approval is therefore not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}